164 related articles for article (PubMed ID: 35665369)
1. Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential.
Liu J; Zhang F; Yu J; Zhao Q
MedComm (2020); 2022 Jun; 3(2):e140. PubMed ID: 35665369
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.
Ba H; Dai Z; Zhang Z; Zhang P; Yin B; Wang J; Li Z; Zhou X
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720496
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway.
Shen C; Zhang Z; Tian Y; Li F; Zhou L; Jiang W; Yang L; Zhang B; Wang L; Zhang Y
BMC Med; 2021 Nov; 19(1):283. PubMed ID: 34819055
[TBL] [Abstract][Full Text] [Related]
4. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
5. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
8. Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer.
Yang CY; Fan MH; Miao CH; Liao YJ; Yuan RH; Liu CL
Mol Ther Oncolytics; 2020 Jun; 17():571-585. PubMed ID: 32637575
[TBL] [Abstract][Full Text] [Related]
9. Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Toews K; Grunewald L; Schwiebert S; Klaus A; Winkler A; Ali S; Zirngibl F; Astrahantseff K; Wagner DL; Henssen AG; Deubzer HE; Schulte JH; Ochsenreither S; Eggert A; Künkele A
Mol Carcinog; 2020 Jul; 59(7):724-735. PubMed ID: 32333465
[TBL] [Abstract][Full Text] [Related]
10. Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors.
Li X; Zhu T; Wang R; Chen J; Tang L; Huo W; Huang X; Cao Q
Adv Mater; 2023 May; 35(19):e2211138. PubMed ID: 36814099
[TBL] [Abstract][Full Text] [Related]
11. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy.
Chen X; Yang S; Li S; Qu Y; Wang HY; Liu J; Dunn ZS; Cinay GE; MacMullan MA; Hu F; Zhang X; Wang P
Mol Ther Oncolytics; 2021 Jun; 21():144-157. PubMed ID: 33981830
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
13. A novel PD-L1-targeted shark V
Li D; English H; Hong J; Liang T; Merlino G; Day CP; Ho M
Mol Ther Oncolytics; 2022 Mar; 24():849-863. PubMed ID: 35317524
[TBL] [Abstract][Full Text] [Related]
14. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Gibbons Johnson RM; Dong H
Front Immunol; 2017; 8():961. PubMed ID: 28848559
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
16. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
Zhang J; Medeiros LJ; Young KH
Front Oncol; 2018; 8():351. PubMed ID: 30250823
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
de Campos NSP; de Oliveira Beserra A; Pereira PHB; Chaves AS; Fonseca FLA; da Silva Medina T; Dos Santos TG; Wang Y; Marasco WA; Suarez ER
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628256
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921
[TBL] [Abstract][Full Text] [Related]
20. APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.
Peng Q; Zhu X; Li C; Xin P; Zheng Y; Liu S
Aging (Albany NY); 2021 Feb; 13(5):7199-7210. PubMed ID: 33653969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
